Browse studies
Find your next paid study
27 recruiting studies matching your filters
Phase 3
Randomized, Open-label, Multicenter Phase 3 Study to Assess the Efficacy and Safety of GIVinostat Versus Hydroxyurea IN JAK2V617F-positive High-risk Polycythemia Vera Patients: the GIV-IN PV TRIAL
The goal of this clinical trial is to compare the efficacy and safety of givinostat to hydroxyurea in Jak2V617F-positive high risk polycythemia vera patients.
Polycythemia Vera
Estimated
~$10 – $7,500
ItalfarmacoNCT06093672
Phase 2
A Randomized Phase 2 Trial of ASTX727 +/- Iadademstat in Accelerated/Blast-Phase Philadelphia Chromosome-Negative Myeloproliferative Neoplasms (MPNs)
This phase II trial compares the effect of ASTX727 in combination with iadademstat to ASTX727 alone in treating patients with accelerated or blast phase Philad…
Accelerated Phase Myeloproliferative NeoplasmBlast Phase Myeloproliferative NeoplasmEssential Thrombocythemia+5 more
Estimated
~$10 – $5,625
National Cancer Institute (NCI)NCT06661915
Phase 2
MethoTRExATE in MyelOpRolifErative Neoplasms (TREATMORE) Trial
Low-dose MTX is a widely used, inexpensive, and safe therapy used for decades and is well tolerated by patients with rheumatologic diseases. Recently, it was i…
Polycythemia Vera (PV)Essential Thrombocythemia (ET)Myelofibrosis (MF)
Estimated
~$10 – $6,250
Icahn School of Medicine at Mount SinaiNCT06541249